Terry D. Butters mostly deals with Biochemistry, Substrate reduction therapy, Glycosphingolipid, Immunology and Enzyme. His research on Biochemistry frequently links to adjacent areas such as Stereochemistry. His biological study spans a wide range of topics, including Glucocerebrosidase, GM2 gangliosidoses, Gangliosidosis and Miglustat.
He has researched Glycosphingolipid in several fields, including Chromatography, Pharmacology, In vivo and Cell biology. His study looks at the relationship between Immunology and fields such as Sandhoff disease, as well as how they intersect with chemical problems. His study in Enzyme is interdisciplinary in nature, drawing from both High-performance liquid chromatography, Glycobiology, Anthranilic acid, Digestion and Monosaccharide.
His primary areas of study are Biochemistry, Stereochemistry, Enzyme, Glycosphingolipid and Glycosylation. His Biochemistry study is mostly concerned with Endoplasmic reticulum, Glycan, Glycolipid, Ceramide and Oligosaccharide. His Stereochemistry study combines topics in areas such as Iminosugar, Biosynthesis, Alkyl and Glycoside hydrolase.
His Glycosphingolipid research is multidisciplinary, incorporating perspectives in Immunology, Miglustat, Ganglioside, Cell biology and Substrate reduction therapy. His studies in Ganglioside integrate themes in fields like HEXB, Sandhoff disease, Endocrinology and Internal medicine. His Glycosylation research includes elements of Mannose and Glycoprotein.
The scientist’s investigation covers issues in Biochemistry, Stereochemistry, Iminosugar, Glycoprotein and Glycan. His Biochemistry study frequently draws connections between related disciplines such as Miglustat. His research in Stereochemistry intersects with topics in Mannosidase, Glycoside hydrolase and Enzyme.
His Iminosugar research is multidisciplinary, incorporating elements of Cystic fibrosis, Dengue virus, Dengue fever, Alkyl and In vivo. His Glycoprotein research integrates issues from Golgi apparatus, Ubiquitin and Glycosylation. The various areas that he examines in his Glycan study include In vitro and Endoplasmic reticulum.
His primary areas of investigation include Stereochemistry, Biochemistry, Iminosugar, Enzyme and Enantiomer. Terry D. Butters combines subjects such as Mannosidase, Miglitol, Cleavage and Disaccharidase with his study of Stereochemistry. His studies in Protein folding, Cystic fibrosis transmembrane conductance regulator, Glucosidases, RNA and Secretion are all subfields of Biochemistry research.
His work deals with themes such as Prodrug, Enzyme assay, Acetylation and Alkyl, which intersect with Iminosugar. Terry D. Butters interconnects Cell culture, Fibroblast and Molecular biology in the investigation of issues within Enzyme. His studies deal with areas such as Miglustat, Maltase, Hydroxymethyl and Maltose as well as Enantiomer.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis
T Cox;R Lachmann;C Hollak;J Aerts.
The Lancet (2000)
N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis.
F M Platt;G R Neises;R A Dwek;T D Butters.
Journal of Biological Chemistry (1994)
Targeting glycosylation as a therapeutic approach
Raymond A. Dwek;Terry D. Butters;Frances M. Platt;Nicole Zitzmann.
Nature Reviews Drug Discovery (2002)
Prevention of Lysosomal Storage in Tay-Sachs Mice Treated with N-Butyldeoxynojirimycin
F M Platt;G R Neises;G Reinkensmeier;M J Townsend.
Science (1997)
Imino sugars inhibit the formation and secretion of bovine viral diarrhea virus, a pestivirus model of hepatitis C virus: Implications for the development of broad spectrum anti-hepatitis virus agents
Nicole Zitzmann;Anand S. Mehta;Sandra Carrouée;Terry D. Butters.
Proceedings of the National Academy of Sciences of the United States of America (1999)
Infantile-onset symptomatic epilepsy syndrome caused by a homozygous loss-of-function mutation of GM3 synthase.
Michael A Simpson;Harold Cross;Christos Proukakis;David A Priestman.
Nature Genetics (2004)
Inhibition of Glycosphingolipid Biosynthesis: Application to Lysosomal Storage Disorders
Terry D. Butters;Raymond A. Dwek;Frances M. Platt.
Chemical Reviews (2000)
Stem cells act through multiple mechanisms to benefit mice with neurodegenerative metabolic disease.
Jean Pyo Lee;Mylvaganam Jeyakumar;Rodolfo Gonzalez;Hiroto Takahashi.
Nature Medicine (2007)
Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease.
D. Elstein;C. Hollak;J. M. F. G. Aerts;S. van Weely.
Journal of Inherited Metabolic Disease (2004)
Imino sugar inhibitors for treating the lysosomal glycosphingolipidoses.
Terry D. Butters;Raymond A. Dwek;Frances M. Platt.
Glycobiology (2005)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
University of Oxford
University of Oxford
University of Oxford
University of Oxford
University of Oxford
University of Toyama
Drexel University
Hokuriku University
University of Poitiers
University College Dublin
Institut Polytechnique de Bordeaux
University of Michigan–Ann Arbor
TU Wien
Heidelberg University
University of California, Los Angeles
Heidelberg University
Chinese Academy of Sciences
American Red Cross
Johns Hopkins University
KU Leuven
Chinese Academy of Sciences
Monash University
Uppsala University
Paris 13 University
University of Cape Town
Johns Hopkins University